CN106509578A - 即食型灵芝、茯苓复合健康饮品的生产方法 - Google Patents
即食型灵芝、茯苓复合健康饮品的生产方法 Download PDFInfo
- Publication number
- CN106509578A CN106509578A CN201610972774.XA CN201610972774A CN106509578A CN 106509578 A CN106509578 A CN 106509578A CN 201610972774 A CN201610972774 A CN 201610972774A CN 106509578 A CN106509578 A CN 106509578A
- Authority
- CN
- China
- Prior art keywords
- poria cocos
- glossy ganoderma
- ultramicro
- ganoderma lucidum
- compound
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 241000222336 Ganoderma Species 0.000 title claims abstract description 131
- 150000001875 compounds Chemical class 0.000 title claims abstract description 65
- 238000004519 manufacturing process Methods 0.000 title claims abstract description 35
- 235000013361 beverage Nutrition 0.000 title abstract description 12
- 241000737241 Cocos Species 0.000 title abstract 6
- 244000197580 Poria cocos Species 0.000 claims abstract description 101
- 235000008599 Poria cocos Nutrition 0.000 claims abstract description 101
- 238000000227 grinding Methods 0.000 claims abstract description 20
- 239000000203 mixture Substances 0.000 claims abstract description 20
- 150000004676 glycans Chemical class 0.000 claims abstract description 14
- 229920001542 oligosaccharide Polymers 0.000 claims abstract description 14
- 239000000084 colloidal system Substances 0.000 claims abstract description 11
- 150000002482 oligosaccharides Chemical class 0.000 claims abstract description 11
- 235000016709 nutrition Nutrition 0.000 claims abstract description 4
- 239000000843 powder Substances 0.000 claims description 44
- 239000004615 ingredient Substances 0.000 claims description 37
- 230000000975 bioactive effect Effects 0.000 claims description 36
- 230000036541 health Effects 0.000 claims description 29
- 239000012535 impurity Substances 0.000 claims description 16
- 239000005030 aluminium foil Substances 0.000 claims description 9
- 238000006253 efflorescence Methods 0.000 claims description 8
- 238000012856 packing Methods 0.000 claims description 8
- 206010037844 rash Diseases 0.000 claims description 8
- -1 Fructose oligosaccharides Chemical class 0.000 claims description 6
- 229930006000 Sucrose Natural products 0.000 claims description 5
- 238000004659 sterilization and disinfection Methods 0.000 claims description 5
- 239000005720 sucrose Substances 0.000 claims description 5
- HDTRYLNUVZCQOY-UHFFFAOYSA-N α-D-glucopyranosyl-α-D-glucopyranoside Natural products OC1C(O)C(O)C(CO)OC1OC1C(O)C(O)C(O)C(CO)O1 HDTRYLNUVZCQOY-UHFFFAOYSA-N 0.000 claims description 2
- 229930091371 Fructose Natural products 0.000 claims description 2
- 239000005715 Fructose Substances 0.000 claims description 2
- 244000068988 Glycine max Species 0.000 claims description 2
- 235000010469 Glycine max Nutrition 0.000 claims description 2
- HDTRYLNUVZCQOY-WSWWMNSNSA-N Trehalose Natural products O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-WSWWMNSNSA-N 0.000 claims description 2
- HDTRYLNUVZCQOY-LIZSDCNHSA-N alpha,alpha-trehalose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-LIZSDCNHSA-N 0.000 claims description 2
- 235000020247 cow milk Nutrition 0.000 claims description 2
- HEBKCHPVOIAQTA-NGQZWQHPSA-N d-xylitol Chemical compound OC[C@H](O)C(O)[C@H](O)CO HEBKCHPVOIAQTA-NGQZWQHPSA-N 0.000 claims description 2
- DLRVVLDZNNYCBX-RTPHMHGBSA-N isomaltose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1OC[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)C(O)O1 DLRVVLDZNNYCBX-RTPHMHGBSA-N 0.000 claims description 2
- 238000001816 cooling Methods 0.000 claims 1
- 210000004185 liver Anatomy 0.000 abstract description 18
- 230000036039 immunity Effects 0.000 abstract description 12
- 229920001282 polysaccharide Polymers 0.000 abstract description 12
- 239000005017 polysaccharide Substances 0.000 abstract description 12
- 230000006870 function Effects 0.000 abstract description 11
- 210000002784 stomach Anatomy 0.000 abstract description 10
- 235000009508 confectionery Nutrition 0.000 abstract description 9
- 239000002994 raw material Substances 0.000 abstract description 8
- 239000000796 flavoring agent Substances 0.000 abstract description 7
- 235000019634 flavors Nutrition 0.000 abstract description 7
- 240000008397 Ganoderma lucidum Species 0.000 abstract description 6
- 238000004806 packaging method and process Methods 0.000 abstract description 6
- 239000000126 substance Substances 0.000 abstract description 6
- 235000019640 taste Nutrition 0.000 abstract description 6
- 235000001637 Ganoderma lucidum Nutrition 0.000 abstract description 5
- 239000004480 active ingredient Substances 0.000 abstract description 5
- 235000013305 food Nutrition 0.000 abstract description 3
- 238000002156 mixing Methods 0.000 abstract description 3
- 239000000049 pigment Substances 0.000 abstract description 3
- 239000003755 preservative agent Substances 0.000 abstract description 3
- 210000000936 intestine Anatomy 0.000 abstract description 2
- 230000035764 nutrition Effects 0.000 abstract description 2
- 238000012545 processing Methods 0.000 abstract description 2
- 230000001954 sterilising effect Effects 0.000 abstract description 2
- 230000001105 regulatory effect Effects 0.000 abstract 1
- 230000000694 effects Effects 0.000 description 28
- 239000008280 blood Substances 0.000 description 16
- 210000004369 blood Anatomy 0.000 description 15
- 210000000952 spleen Anatomy 0.000 description 12
- 150000003648 triterpenes Chemical class 0.000 description 11
- 241000207961 Sesamum Species 0.000 description 10
- 235000003434 Sesamum indicum Nutrition 0.000 description 10
- 230000009286 beneficial effect Effects 0.000 description 10
- 239000003814 drug Substances 0.000 description 10
- 238000001704 evaporation Methods 0.000 description 9
- 230000000259 anti-tumor effect Effects 0.000 description 8
- 201000010099 disease Diseases 0.000 description 8
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 8
- 230000036528 appetite Effects 0.000 description 7
- 235000019789 appetite Nutrition 0.000 description 7
- 239000003795 chemical substances by application Substances 0.000 description 7
- 230000001976 improved effect Effects 0.000 description 7
- 206010028980 Neoplasm Diseases 0.000 description 6
- 208000004880 Polyuria Diseases 0.000 description 6
- 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 description 6
- 238000010521 absorption reaction Methods 0.000 description 6
- 230000033228 biological regulation Effects 0.000 description 6
- 201000011510 cancer Diseases 0.000 description 6
- 210000004027 cell Anatomy 0.000 description 6
- 230000035619 diuresis Effects 0.000 description 6
- 230000036737 immune function Effects 0.000 description 6
- 206010022437 insomnia Diseases 0.000 description 6
- 238000000034 method Methods 0.000 description 6
- 231100000252 nontoxic Toxicity 0.000 description 6
- 230000003000 nontoxic effect Effects 0.000 description 6
- 241000894006 Bacteria Species 0.000 description 5
- 241001619461 Poria <basidiomycete fungus> Species 0.000 description 5
- 230000003712 anti-aging effect Effects 0.000 description 5
- 230000008901 benefit Effects 0.000 description 5
- 230000001965 increasing effect Effects 0.000 description 5
- 210000004072 lung Anatomy 0.000 description 5
- NTYJJOPFIAHURM-UHFFFAOYSA-N Histamine Chemical compound NCCC1=CN=CN1 NTYJJOPFIAHURM-UHFFFAOYSA-N 0.000 description 4
- 230000032683 aging Effects 0.000 description 4
- 229930013930 alkaloid Natural products 0.000 description 4
- 150000003797 alkaloid derivatives Chemical class 0.000 description 4
- 239000003963 antioxidant agent Substances 0.000 description 4
- 230000003078 antioxidant effect Effects 0.000 description 4
- 229940079593 drug Drugs 0.000 description 4
- 229910052732 germanium Inorganic materials 0.000 description 4
- 239000003292 glue Substances 0.000 description 4
- 230000002218 hypoglycaemic effect Effects 0.000 description 4
- 229910052500 inorganic mineral Inorganic materials 0.000 description 4
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 4
- 150000002632 lipids Chemical class 0.000 description 4
- 239000000463 material Substances 0.000 description 4
- 239000011707 mineral Substances 0.000 description 4
- 235000010755 mineral Nutrition 0.000 description 4
- 210000005036 nerve Anatomy 0.000 description 4
- 229920001184 polypeptide Polymers 0.000 description 4
- 102000004196 processed proteins & peptides Human genes 0.000 description 4
- 108090000765 processed proteins & peptides Proteins 0.000 description 4
- 230000001737 promoting effect Effects 0.000 description 4
- 102000004169 proteins and genes Human genes 0.000 description 4
- 230000001603 reducing effect Effects 0.000 description 4
- 230000002829 reductive effect Effects 0.000 description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
- OILXMJHPFNGGTO-UHFFFAOYSA-N (22E)-(24xi)-24-methylcholesta-5,22-dien-3beta-ol Natural products C1C=C2CC(O)CCC2(C)C2C1C1CCC(C(C)C=CC(C)C(C)C)C1(C)CC2 OILXMJHPFNGGTO-UHFFFAOYSA-N 0.000 description 3
- RQOCXCFLRBRBCS-UHFFFAOYSA-N (22E)-cholesta-5,7,22-trien-3beta-ol Natural products C1C(O)CCC2(C)C(CCC3(C(C(C)C=CCC(C)C)CCC33)C)C3=CC=C21 RQOCXCFLRBRBCS-UHFFFAOYSA-N 0.000 description 3
- OQMZNAMGEHIHNN-UHFFFAOYSA-N 7-Dehydrostigmasterol Natural products C1C(O)CCC2(C)C(CCC3(C(C(C)C=CC(CC)C(C)C)CCC33)C)C3=CC=C21 OQMZNAMGEHIHNN-UHFFFAOYSA-N 0.000 description 3
- 244000025254 Cannabis sativa Species 0.000 description 3
- 206010011224 Cough Diseases 0.000 description 3
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 3
- 206010012735 Diarrhoea Diseases 0.000 description 3
- DNVPQKQSNYMLRS-NXVQYWJNSA-N Ergosterol Natural products CC(C)[C@@H](C)C=C[C@H](C)[C@H]1CC[C@H]2C3=CC=C4C[C@@H](O)CC[C@]4(C)[C@@H]3CC[C@]12C DNVPQKQSNYMLRS-NXVQYWJNSA-N 0.000 description 3
- 229930195725 Mannitol Natural products 0.000 description 3
- 206010030113 Oedema Diseases 0.000 description 3
- 206010033557 Palpitations Diseases 0.000 description 3
- 241000222341 Polyporaceae Species 0.000 description 3
- 208000006011 Stroke Diseases 0.000 description 3
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 3
- 230000002929 anti-fatigue Effects 0.000 description 3
- 235000006708 antioxidants Nutrition 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- BHQCQFFYRZLCQQ-OELDTZBJSA-N cholic acid Chemical compound C([C@H]1C[C@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(O)=O)C)[C@@]2(C)[C@@H](O)C1 BHQCQFFYRZLCQQ-OELDTZBJSA-N 0.000 description 3
- 230000006378 damage Effects 0.000 description 3
- 230000007812 deficiency Effects 0.000 description 3
- 206010012601 diabetes mellitus Diseases 0.000 description 3
- 239000003792 electrolyte Substances 0.000 description 3
- 238000005516 engineering process Methods 0.000 description 3
- DNVPQKQSNYMLRS-SOWFXMKYSA-N ergosterol Chemical compound C1[C@@H](O)CC[C@]2(C)[C@H](CC[C@]3([C@H]([C@H](C)/C=C/[C@@H](C)C(C)C)CC[C@H]33)C)C3=CC=C21 DNVPQKQSNYMLRS-SOWFXMKYSA-N 0.000 description 3
- 239000007789 gas Substances 0.000 description 3
- GNPVGFCGXDBREM-UHFFFAOYSA-N germanium atom Chemical compound [Ge] GNPVGFCGXDBREM-UHFFFAOYSA-N 0.000 description 3
- 230000012010 growth Effects 0.000 description 3
- 210000002216 heart Anatomy 0.000 description 3
- 230000001900 immune effect Effects 0.000 description 3
- 239000000594 mannitol Substances 0.000 description 3
- 235000010355 mannitol Nutrition 0.000 description 3
- 230000004060 metabolic process Effects 0.000 description 3
- VYQNWZOUAUKGHI-UHFFFAOYSA-N monobenzone Chemical compound C1=CC(O)=CC=C1OCC1=CC=CC=C1 VYQNWZOUAUKGHI-UHFFFAOYSA-N 0.000 description 3
- 230000002265 prevention Effects 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- 150000003254 radicals Chemical class 0.000 description 3
- 239000007787 solid Substances 0.000 description 3
- 235000015096 spirit Nutrition 0.000 description 3
- 208000024891 symptom Diseases 0.000 description 3
- BHQCQFFYRZLCQQ-UHFFFAOYSA-N (3alpha,5alpha,7alpha,12alpha)-3,7,12-trihydroxy-cholan-24-oic acid Natural products OC1CC2CC(O)CCC2(C)C2C1C1CCC(C(CCC(O)=O)C)C1(C)C(O)C2 BHQCQFFYRZLCQQ-UHFFFAOYSA-N 0.000 description 2
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 2
- 206010008190 Cerebrovascular accident Diseases 0.000 description 2
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 2
- 239000004380 Cholic acid Substances 0.000 description 2
- 206010008909 Chronic Hepatitis Diseases 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 2
- 241000233866 Fungi Species 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 2
- 206010062717 Increased upper airway secretion Diseases 0.000 description 2
- 102000004877 Insulin Human genes 0.000 description 2
- 108090001061 Insulin Proteins 0.000 description 2
- 208000007443 Neurasthenia Diseases 0.000 description 2
- 108091005461 Nucleic proteins Proteins 0.000 description 2
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 2
- 208000025865 Ulcer Diseases 0.000 description 2
- 206010047700 Vomiting Diseases 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 230000003266 anti-allergic effect Effects 0.000 description 2
- 230000003471 anti-radiation Effects 0.000 description 2
- 230000001147 anti-toxic effect Effects 0.000 description 2
- 206010003549 asthenia Diseases 0.000 description 2
- 208000006673 asthma Diseases 0.000 description 2
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 2
- 230000001580 bacterial effect Effects 0.000 description 2
- 235000019658 bitter taste Nutrition 0.000 description 2
- RYYVLZVUVIJVGH-UHFFFAOYSA-N caffeine Chemical compound CN1C(=O)N(C)C(=O)C2=C1N=CN2C RYYVLZVUVIJVGH-UHFFFAOYSA-N 0.000 description 2
- 239000011575 calcium Substances 0.000 description 2
- 229910052791 calcium Inorganic materials 0.000 description 2
- 210000003169 central nervous system Anatomy 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 239000000460 chlorine Substances 0.000 description 2
- 229910052801 chlorine Inorganic materials 0.000 description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
- 235000019416 cholic acid Nutrition 0.000 description 2
- 229960002471 cholic acid Drugs 0.000 description 2
- KXGVEGMKQFWNSR-UHFFFAOYSA-N deoxycholic acid Natural products C1CC2CC(O)CCC2(C)C2C1C1CCC(C(CCC(O)=O)C)C1(C)C(O)C2 KXGVEGMKQFWNSR-UHFFFAOYSA-N 0.000 description 2
- 235000013325 dietary fiber Nutrition 0.000 description 2
- 208000002173 dizziness Diseases 0.000 description 2
- 229930003944 flavone Natural products 0.000 description 2
- 150000002213 flavones Chemical class 0.000 description 2
- 235000011949 flavones Nutrition 0.000 description 2
- 239000012530 fluid Substances 0.000 description 2
- 239000008103 glucose Substances 0.000 description 2
- 231100000753 hepatic injury Toxicity 0.000 description 2
- 208000006454 hepatitis Diseases 0.000 description 2
- 230000002443 hepatoprotective effect Effects 0.000 description 2
- 229960001340 histamine Drugs 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 230000001939 inductive effect Effects 0.000 description 2
- 229940125396 insulin Drugs 0.000 description 2
- 210000003734 kidney Anatomy 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- 201000007270 liver cancer Diseases 0.000 description 2
- 208000014018 liver neoplasm Diseases 0.000 description 2
- 230000033001 locomotion Effects 0.000 description 2
- 235000020845 low-calorie diet Nutrition 0.000 description 2
- 210000002540 macrophage Anatomy 0.000 description 2
- 230000004089 microcirculation Effects 0.000 description 2
- 210000003205 muscle Anatomy 0.000 description 2
- 102000039446 nucleic acids Human genes 0.000 description 2
- 108020004707 nucleic acids Proteins 0.000 description 2
- 150000007523 nucleic acids Chemical class 0.000 description 2
- 235000008935 nutritious Nutrition 0.000 description 2
- 239000001301 oxygen Substances 0.000 description 2
- 229910052760 oxygen Inorganic materials 0.000 description 2
- 208000026435 phlegm Diseases 0.000 description 2
- 239000002574 poison Substances 0.000 description 2
- 231100000614 poison Toxicity 0.000 description 2
- 239000011591 potassium Substances 0.000 description 2
- 229910052700 potassium Inorganic materials 0.000 description 2
- 230000002335 preservative effect Effects 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 230000000717 retained effect Effects 0.000 description 2
- 230000028327 secretion Effects 0.000 description 2
- 239000000932 sedative agent Substances 0.000 description 2
- 230000001624 sedative effect Effects 0.000 description 2
- 239000011734 sodium Substances 0.000 description 2
- 229910052708 sodium Inorganic materials 0.000 description 2
- 238000005728 strengthening Methods 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 239000003053 toxin Substances 0.000 description 2
- 231100000765 toxin Toxicity 0.000 description 2
- 231100000397 ulcer Toxicity 0.000 description 2
- 230000008673 vomiting Effects 0.000 description 2
- MBDOYVRWFFCFHM-SNAWJCMRSA-N (2E)-hexenal Chemical compound CCC\C=C\C=O MBDOYVRWFFCFHM-SNAWJCMRSA-N 0.000 description 1
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 1
- 241000222382 Agaricomycotina Species 0.000 description 1
- 206010002383 Angina Pectoris Diseases 0.000 description 1
- 241000186000 Bifidobacterium Species 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 241000282461 Canis lupus Species 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- 208000008964 Chemical and Drug Induced Liver Injury Diseases 0.000 description 1
- 208000017667 Chronic Disease Diseases 0.000 description 1
- CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 description 1
- 230000006820 DNA synthesis Effects 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 206010016654 Fibrosis Diseases 0.000 description 1
- 206010018612 Gonorrhoea Diseases 0.000 description 1
- 206010019233 Headaches Diseases 0.000 description 1
- 208000006083 Hypokinesia Diseases 0.000 description 1
- 208000001953 Hypotension Diseases 0.000 description 1
- 102000000588 Interleukin-2 Human genes 0.000 description 1
- 108010002350 Interleukin-2 Proteins 0.000 description 1
- 244000017020 Ipomoea batatas Species 0.000 description 1
- 235000002678 Ipomoea batatas Nutrition 0.000 description 1
- LPHGQDQBBGAPDZ-UHFFFAOYSA-N Isocaffeine Natural products CN1C(=O)N(C)C(=O)C2=C1N(C)C=N2 LPHGQDQBBGAPDZ-UHFFFAOYSA-N 0.000 description 1
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 description 1
- 102000004895 Lipoproteins Human genes 0.000 description 1
- 108090001030 Lipoproteins Proteins 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- 206010059013 Nocturnal emission Diseases 0.000 description 1
- 108091093105 Nuclear DNA Proteins 0.000 description 1
- 208000008589 Obesity Diseases 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 235000001188 Peltandra virginica Nutrition 0.000 description 1
- 235000008331 Pinus X rigitaeda Nutrition 0.000 description 1
- 235000011613 Pinus brutia Nutrition 0.000 description 1
- 241000018646 Pinus brutia Species 0.000 description 1
- 208000005374 Poisoning Diseases 0.000 description 1
- 241000222383 Polyporales Species 0.000 description 1
- WCUXLLCKKVVCTQ-UHFFFAOYSA-M Potassium chloride Chemical compound [Cl-].[K+] WCUXLLCKKVVCTQ-UHFFFAOYSA-M 0.000 description 1
- 208000001431 Psychomotor Agitation Diseases 0.000 description 1
- 206010038743 Restlessness Diseases 0.000 description 1
- 241000576755 Sclerotia Species 0.000 description 1
- 206010039897 Sedation Diseases 0.000 description 1
- 208000005392 Spasm Diseases 0.000 description 1
- 102000019197 Superoxide Dismutase Human genes 0.000 description 1
- 108010012715 Superoxide dismutase Proteins 0.000 description 1
- 210000001744 T-lymphocyte Anatomy 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 239000012190 activator Substances 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 239000003905 agrochemical Substances 0.000 description 1
- 229910021529 ammonia Inorganic materials 0.000 description 1
- 239000002269 analeptic agent Substances 0.000 description 1
- 230000000146 antalgic effect Effects 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 230000001093 anti-cancer Effects 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 230000002225 anti-radical effect Effects 0.000 description 1
- 230000003260 anti-sepsis Effects 0.000 description 1
- 239000002246 antineoplastic agent Substances 0.000 description 1
- 230000001363 autoimmune Effects 0.000 description 1
- 230000002457 bidirectional effect Effects 0.000 description 1
- 239000003181 biological factor Substances 0.000 description 1
- 235000007215 black sesame Nutrition 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 238000009835 boiling Methods 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 238000009395 breeding Methods 0.000 description 1
- 230000001488 breeding effect Effects 0.000 description 1
- 229960001948 caffeine Drugs 0.000 description 1
- VJEONQKOZGKCAK-UHFFFAOYSA-N caffeine Natural products CN1C(=O)N(C)C(=O)C2=C1C=CN2C VJEONQKOZGKCAK-UHFFFAOYSA-N 0.000 description 1
- 230000001914 calming effect Effects 0.000 description 1
- 230000032677 cell aging Effects 0.000 description 1
- 230000007969 cellular immunity Effects 0.000 description 1
- 229940044683 chemotherapy drug Drugs 0.000 description 1
- 229940099352 cholate Drugs 0.000 description 1
- 229960001231 choline Drugs 0.000 description 1
- OEYIOHPDSNJKLS-UHFFFAOYSA-N choline Chemical compound C[N+](C)(C)CCO OEYIOHPDSNJKLS-UHFFFAOYSA-N 0.000 description 1
- 208000013116 chronic cough Diseases 0.000 description 1
- 230000007882 cirrhosis Effects 0.000 description 1
- 208000019425 cirrhosis of liver Diseases 0.000 description 1
- 208000029078 coronary artery disease Diseases 0.000 description 1
- 210000004351 coronary vessel Anatomy 0.000 description 1
- 229930182483 coumarin glycoside Natural products 0.000 description 1
- 150000008140 coumarin glycosides Chemical class 0.000 description 1
- 229960004397 cyclophosphamide Drugs 0.000 description 1
- 231100000433 cytotoxic Toxicity 0.000 description 1
- 230000001472 cytotoxic effect Effects 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 210000002249 digestive system Anatomy 0.000 description 1
- 230000008034 disappearance Effects 0.000 description 1
- 231100000673 dose–response relationship Toxicity 0.000 description 1
- 230000035622 drinking Effects 0.000 description 1
- 201000006549 dyspepsia Diseases 0.000 description 1
- 230000000517 effect on sleep Effects 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 239000003797 essential amino acid Substances 0.000 description 1
- 235000020776 essential amino acid Nutrition 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 230000004438 eyesight Effects 0.000 description 1
- 230000001815 facial effect Effects 0.000 description 1
- 210000002468 fat body Anatomy 0.000 description 1
- 206010016256 fatigue Diseases 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 238000000855 fermentation Methods 0.000 description 1
- 230000004151 fermentation Effects 0.000 description 1
- 239000001530 fumaric acid Substances 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 230000003394 haemopoietic effect Effects 0.000 description 1
- 210000003128 head Anatomy 0.000 description 1
- 231100000869 headache Toxicity 0.000 description 1
- 229910001385 heavy metal Inorganic materials 0.000 description 1
- 210000005096 hematological system Anatomy 0.000 description 1
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 1
- 229960002885 histidine Drugs 0.000 description 1
- 208000021822 hypotensive Diseases 0.000 description 1
- 230000001077 hypotensive effect Effects 0.000 description 1
- 230000005934 immune activation Effects 0.000 description 1
- 230000002434 immunopotentiative effect Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- 229910052742 iron Inorganic materials 0.000 description 1
- 239000010977 jade Substances 0.000 description 1
- 208000037805 labour Diseases 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 238000002386 leaching Methods 0.000 description 1
- 239000000787 lecithin Substances 0.000 description 1
- 229940067606 lecithin Drugs 0.000 description 1
- 235000010445 lecithin Nutrition 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 201000002364 leukopenia Diseases 0.000 description 1
- 208000019423 liver disease Diseases 0.000 description 1
- 230000003908 liver function Effects 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 229910052748 manganese Inorganic materials 0.000 description 1
- 235000012054 meals Nutrition 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 206010027175 memory impairment Diseases 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 230000027939 micturition Effects 0.000 description 1
- 230000000116 mitigating effect Effects 0.000 description 1
- 230000004899 motility Effects 0.000 description 1
- 210000000214 mouth Anatomy 0.000 description 1
- 230000002107 myocardial effect Effects 0.000 description 1
- 208000031225 myocardial ischemia Diseases 0.000 description 1
- 210000004165 myocardium Anatomy 0.000 description 1
- 210000000822 natural killer cell Anatomy 0.000 description 1
- 239000003176 neuroleptic agent Substances 0.000 description 1
- 230000000701 neuroleptic effect Effects 0.000 description 1
- 231100000957 no side effect Toxicity 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 230000000050 nutritive effect Effects 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 238000009329 organic farming Methods 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 230000000242 pagocytic effect Effects 0.000 description 1
- 230000035699 permeability Effects 0.000 description 1
- 229910052698 phosphorus Inorganic materials 0.000 description 1
- 231100000572 poisoning Toxicity 0.000 description 1
- 230000000607 poisoning effect Effects 0.000 description 1
- 239000001103 potassium chloride Substances 0.000 description 1
- 235000011164 potassium chloride Nutrition 0.000 description 1
- 238000004321 preservation Methods 0.000 description 1
- 230000003449 preventive effect Effects 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 208000020016 psychiatric disease Diseases 0.000 description 1
- 238000010298 pulverizing process Methods 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000036280 sedation Effects 0.000 description 1
- 230000003860 sleep quality Effects 0.000 description 1
- 208000010110 spontaneous platelet aggregation Diseases 0.000 description 1
- 150000003431 steroids Chemical class 0.000 description 1
- 239000004575 stone Substances 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 235000021147 sweet food Nutrition 0.000 description 1
- 235000019605 sweet taste sensations Nutrition 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 235000013619 trace mineral Nutrition 0.000 description 1
- 239000011573 trace mineral Substances 0.000 description 1
- 230000002936 tranquilizing effect Effects 0.000 description 1
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 1
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 1
- 239000011800 void material Substances 0.000 description 1
- 229910052725 zinc Inorganic materials 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L2/00—Non-alcoholic beverages; Dry compositions or concentrates therefor; Their preparation
- A23L2/385—Concentrates of non-alcoholic beverages
- A23L2/39—Dry compositions
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L2/00—Non-alcoholic beverages; Dry compositions or concentrates therefor; Their preparation
- A23L2/52—Adding ingredients
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L2/00—Non-alcoholic beverages; Dry compositions or concentrates therefor; Their preparation
- A23L2/52—Adding ingredients
- A23L2/60—Sweeteners
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
Landscapes
- Health & Medical Sciences (AREA)
- Nutrition Science (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
本发明属于食品加工技术领域,具体涉及一种即食型富含生物活性成分的灵芝、茯苓复合健康饮品的生产方法。具体步骤包括:富含生物活性成分的灵芝粉化‑富含生物活性成分的茯苓粉化‑调配(+低聚糖)‑胶体化‑分装‑杀菌。本发明以野生或生态有机种植得到的优质灵芝和茯苓为原料制作复合饮品,绿色无公害,经过超微粉碎、胶磨均质,使饮品中富含水溶性多糖(灵芝多糖、茯苓多糖),极易被人体利用,具有调节免疫力、抗疲劳、护肝、护肠胃等保健功能。本发明的产品配方中不加化学防腐剂和色素,对人体安全,而且饮用方便;生产得到的饮品保留了灵芝和茯苓的原汁原味,风味独特、口感甘甜爽滑,稳定性好,营养丰富。
Description
技术领域
本发明属于食品加工技术领域,具体涉及一种即食型富含生物活性成分的灵芝、茯苓复合健康饮品的生产方法。
背景技术
灵芝又称灵芝草、神芝、芝草、仙草、瑞草,林中灵、琼珍,学名:Ganoderma LucidumKarst,是多孔菌科真菌灵芝的子实体。根据我国第一部药物专著《神农本草经》记载:灵芝有紫、赤、青、黄、白、黑六种,性味甘平。灵芝原产于亚洲东部,中国古代认为灵芝具有长生不老、起死回生的功效,视为仙草。 灵芝主要分布在中国、朝鲜半岛和日本。灵芝一般生长在湿度高且光线昏暗的山林中,主要生长在腐树或是其树木的根部。灵芝一词最早出现在东汉张衡《西京赋》:“浸石菌于重涯,濯灵芝以朱柯”之中。甘,平。归心、肺、肝、肾经。主治虚劳、咳嗽、气喘、失眠、消化不良,恶性肿瘤等。
青芝:一名龙芝,酸、平、无毒。明目,补肝,安神,增强记忆力。 赤芝:一名丹芝,苦、平、无毒。解胸胃郁结,补中益气,使人神志清明。 黄芝:一名金芝,甘、平、无毒。益脾胃,安神。 白芝:一名玉芝、素芝,辛、平、无毒。止咳益肺,安神,亦增强体力。 黑芝:一名玄芝,咸、平、无毒。利水道,益肾气。 紫芝:一名木芝甘、温、无毒。益精气,坚筋骨,利关节,疗虚劳。
灵芝属的化学成分较为复杂, 且因所用菌种、菌种产地、栽培方法、提取工艺、制剂方法不同而各异。其中有效成份可分为十大类,包括灵芝多糖、灵芝多肽、三萜类、16种氨基酸(其中含有七种人体必需氨基酸)、蛋白质、甾类、甘露醇、香豆精苷、生物碱、有机酸(主含延胡索酸),以及微量元素Ge、P、Fe、Ca、Mn、Zn、等。灵芝多糖是灵芝的主要有效成分之一,具有抗肿瘤、免疫调节、降血糖、抗氧化、降血脂与抗衰老作用。灵芝所含三萜类不下百余种, 其中以四环三萜类为主, 灵芝的苦味与所含三萜类有关。三萜类也是灵芝的有效成分之一, 对人肝癌细胞具有细胞毒作用, 也能抑制组织胺的释放, 具有保肝作用和具有抗过敏作用等。(1)灵芝味甘苦、性平,归心、肺、肝、脾经;可养心安神,养肺益气,理气化淤、滋肝健脾。主治虚劳体弱,神疲乏力,心悸失眠,头目昏晕,久咳气喘,食欲不振,反应迟钝,呼吸短促等症。(2)灵芝含有的“锗”,能使人体血液吸收氧的能力增加1.5倍,因此可以促进新陈代谢并有延缓老化的作用,还有增强皮肤本身修护功能的功效,可用于各种慢性病所致的面色黄萎及由于气血不足而致的面部光泽等症;灵芝所含有机锗可诱导人体产生并激活NK细胞和巨噬细胞活性,参与免疫调节。(3)灵芝中的多糖具有双向调节机体免疫力,抗肿瘤和护肝的作用;灵芝中的生物碱可以抗炎镇痛;灵芝孢子粉能止血、排毒、抗氧。
1.抗肿瘤:自身免疫功能的低下或失调,是肿瘤之所以会发生并扩展的重要原因。灵芝是最佳的免疫功能调节和激活剂,它可显著提高机体的免疫功能,增强患者自身的抗癌能力。 灵芝可以通过促进白细胞介素-2的生成,通过促进单核巨噬细胞的吞噬功能、通过提升人体的造血能力尤其是白细胞的指标水平,以及通过其中某些有效成分对癌细胞的抑制作用,成为抗肿瘤、防癌以及癌症辅助治疗的优选药物。灵芝对人体几乎没有任何毒副作用。这种无毒性的免疫活化剂的优点,恰恰是许多肿瘤化疗药物和其它免疫促进剂都不具有的。
2.保肝解毒:灵芝对多种理化及生物因素引起的肝损伤有保护作用。无论在肝脏损害发生前还是发生后,服用灵芝都可保护肝脏,减轻肝损伤。灵芝能促进肝脏对药物、毒物的代谢,对于中毒性肝炎有确切的疗效。尤其是慢性肝炎,灵芝可明显消除头晕、乏力、恶心、肝区不适等症状,并可有效地改善肝功能,使各项指标趋于正常。 所以,灵芝可用于治疗慢性中毒、各类慢性肝炎、肝硬化、肝功能障碍。
3.防治心血管疾病:动物实验和临床试验均表明,灵芝可有效地扩张冠状动脉,增加冠脉血流量,改善心肌微循环,增强心肌氧和能量的供给,因此,对心肌缺血具有保护作用,可广泛用于冠心病、心绞痛等的治疗和预防。
4.防治高血脂:对高血脂病患者,灵芝可明显降低血胆固醇、脂蛋白和甘油三脂,并能预防动脉粥样硬化斑块的形成。对于粥样硬化斑块已经形成者,则有降低动脉壁胆固醇含量、软化血管、防止进一步损伤的作用。
5.防治中风:可改善局部微循环,阻止血小板聚集。这些功效对于多种类型的中风有良好的防治作用。
6.抗衰老:灵芝所含的多糖、多肽等有着明显的延缓衰老功效。此功效主要基于以下机理:
(1)促进和调整免疫功能。对于成年人和老年人而言,这种促进和调整可明显延缓衰老。对于处于生长发育阶段的少年儿童而言,则可促进其免疫功能的完善,增强抗病能力,确保其健康成长。(2)调节代谢平衡,促进核酸和蛋白质的合成。研究表明,灵芝能促时血清、肝脏和骨髓的核酸及蛋白质的生物合成,因此可以有效地抗病防衰老。观察表明,服用灵芝以抗衰老,不仅对老年人有益,对务年龄阶段的人士都适用,因为生长发育的过程,也就是走向衰老的过程。(3)抗自由基作用。生物体所产生的内原性防卫自由基损伤的抗氧化剂或抗氧化剂化酶类物质(如超氧化物歧化酶,SOD)的降低,是人体衰老的一个原因。灵芝多糖有显著的拟SOD活性,可显著清除机体产生的自由基,从而阻止自由基对机体的损伤,防止了脂体的过氧化,保护了细胞,延缓了细胞衰老。(4)灵芝多糖能显箸促进细胞核内DNA合成能力,并可增加细胞的***代数,从而延缓了机体的衰老。 7.抗神经衰弱;灵芝就已用于神经衰弱症与失眠,故它对中枢起到良好的作用。提取物能激发运动性抑制,使运动性降低,使协调运动失调、呈现用量依赖性镇病效果,对环已巴比妥睡眠作用能缩短睡眠时间,能延长中枢兴奋药咖啡因致痉挛及死亡的时间,这些结果表明,灵芝对中枢呈抑制性作用。祖国医药所载灵芝能“安神”、“增智慧”、“不忘”。据报道,灵芝制剂对神经衰弱失眠有显著疗效,总有效率高达87.14%~100%。一般用药后10~15天即出现明显疗效,表明为睡眠改善,食欲、体重增加,心悸、头痛、头晕减轻或消失,精神振奋,记忆力增强。属气血两虚者疗效更好。所以,灵芝对于中枢神经***有较强的调节作用,具有镇静安神的功效,对于神通衰弱和失眠患者是必备佳品,国家药典中,灵芝就是有效的安眠宁神之药。
茯苓,中药名,为多孔菌科真菌茯苓的干燥菌核。茯苓(学名:Poria cocos(Schw.)Wolf.)属菌物界,担子菌亚门,层菌纲,非褶菌目,多孔菌科,卧孔属,被古人称为“四时神药”,在我国有着悠久的药用历史,具有利水渗湿、益脾和胃、宁心安神、抗肿瘤等功效。产地:主产于云南省的丽江、兰坪、维西、剑川、楚雄。安徽省的金寨、霍山、岳西、太湖。湖北省的英山、罗田、麻城。河南省的商城、固始、新县。广西自治区的梧州地区。此外浙江、广东、湖南、江苏、福建、江西均有生产。华北、西北、东北等地亦有分布。主要成分:含茯苓多糖、茯苓酸、蛋白质、脂肪、卵磷脂、组胺酸、胆硷、麦角甾醇和钾盐等。性味:甘、平。归经:入心、脾、胃、肺、肾经。功能:利水渗湿,益脾宁心。主治:气虚劳伤,水肿,痰饮,呕吐,腹泻,遗精,热淋,惊悸,健忘等症。茯苓,俗称云苓、松苓、茯灵,为寄生在松树根上的菌类植物,形状像甘薯,外皮黑褐色,里面白色或粉红色。茯苓能增强机体免疫功能,茯苓多糖有明显的抗肿瘤作用;有利尿作用,能增加尿中钾、钠、氯等电解质的排出;有镇静及保护肝脏、抑制溃疡的发生、降血糖、抗放射等作用。茯苓还用作茯苓饼、茯苓酥和茯苓酒等。有的国家将茯苓作为海军常用药物及滋补品的原料。在温度较大的地区和场所,茯苓可作为重要的食疗品种,经常食用可健脾去湿,助消化,壮体质。茯苓的功效与作用:茯苓味甘、淡、性平,能渗湿利水;健脾和胃;宁心安神。主治小便不利;水肿胀满;痰饮咳逆;呕吐;脾虚食少;泄泻;心悸不安;失眠健忘;遗精白浊。1.利水消肿:茯苓有利水、消肿、固精、安神、健脾胃等多种功能。2.提高人体免疫力:茯苓还可提高人体免疫功能,有防癌抗癌之功效。3.降血压:茯苓可使平滑肌收缩振幅减少,张力下降。茯苓可影响体内代谢,对电解质的平衡有调解作用,并能降低血糖,抑制毛细血管的通透性。4.抗菌作用。5.对消化***的影响:白茯苓对家兔离体肠管有直接松弛作用。6.抗肿瘤作用:白茯苓中的主要成分为白茯苓聚糖,含量很高。7.白茯苓多糖体对免疫功能的影响:各种白茯苓多糖体在体内均能增强T淋巴细胞的细胞毒性作用。8.对血液***的影响:能使环磷酰胺所致大白鼠白细胞减少加速回升。9.对中枢神经***的影响:白茯苓有镇静作用。10.白茯苓可健脾,对那些久病瘦弱、食欲不振或兼有体倦乏力、腹泻的气虚脾弱病人有扶脾益气的作用,而且药性平和。
以富含生物活性成分的灵芝/富含生物活性成分的茯苓为原料制作复合健康饮品,经过超细化、胶磨,使饮品中富含灵芝多糖、茯苓多糖,极易被人体吸收利用,具有调节免疫力、抗疲劳、护肝、护肠胃等保健功能。
发明内容
本发明的目的是提供一种以野生或生态有机种植的富含生物活性成分的灵芝和以野生或生态有机种植的富含生物活性成分的茯苓为主要原料的复合健康饮品的生产方法,该生产方法工艺简洁,生产得到的复合饮品保留了灵芝和茯苓的原汁原味,风味独特、口感甘甜爽滑,稳定性好,含有丰富的灵芝多糖和茯苓多糖,营养丰富,利于被人体吸收消化,能提高人体的免疫力,具有很好的保健作用。
为实现上述目的,本发明采用如下的技术方案:
一种即食型的灵芝、茯苓复合健康饮品的生产方法,具体步骤如下:
(1)富含生物活性成分的灵芝粉化:取野生或生态有机种植的干品灵芝,除杂,进行过500-2000目的超微粉碎,取得灵芝超微粉;
(2)富含生物活性成分的茯苓粉化:取野生或生态有机种植的干品茯苓,除杂,进行过500-2000目的超微粉碎,取得茯苓超微粉;
(3)调配:将步骤(1)和(2)得到的超微粉中,按照重量比灵芝超微粉: 茯苓超微粉为1:1-1:5的比例调配, 得到混合物,然后再按照混合物:低聚糖为5-20:50-100的比例加入低聚糖进行混合;
(4)胶体化:过胶体磨磨浆均质,实施胶体化一小时以上;生产过程不使用水,以低聚糖为分散剂载体;胶体化的好处有能够将打成超细的灵芝超微粉和茯苓超微粉完全均质,形成物理形态完全组合在一起的物质,产品中生物活性成分(多糖、多肽、三萜类、麦角甾醇、甘露醇、黄酮、生物碱等不丢失),还能够减少有害物质的侵入,免蒸煮,保质时间延长到到15-20个月不变质。
(5)分装杀菌:分装铝箔袋或塑料袋后,于1500w微波下,杀菌30-60秒,冷却、检验、得到成品。微波杀菌的好处是一是进一步减少水分。二是高度灭菌,延长保质时间,
上述的即食型的灵芝、茯苓复合健康饮品的生产方法,步骤(3)中所述的低聚糖包括:果糖低聚糖、异麦芽低聚糖、蔗糖低聚糖、牛乳低聚糖、海藻糖、低聚木糖、大豆低聚糖和半乳糖低聚糖。
上述的富含生物活性成分的灵芝、茯苓复合健康饮品的生产方法中,所述的灵芝为野生或有机种植的干品灵芝。
本发明的有益效果:
1、本发明的免蒸煮即食型富含生物活性成分的灵芝、茯苓复合健康饮品的生产方法中,所用的灵芝是野生或有机种植获得的,其农药及重金属残留低,而且锗元素的含量高,用来制作成饮品,能提高饮品中有机锗的含量,从而使人们在饮用后提高了对锗元素的摄入量。富含生物活性成分的灵芝中还含有丰富的灵芝多糖,灵芝多糖是灵芝的主要有效成分之一, 具有抗肿瘤、免疫调节、降血糖、抗氧化、降血脂与抗衰老作用。灵芝所含三萜类不下百余种, 其中以四环三萜类为主, 灵芝的苦味与所含三萜类有关。三萜类也是灵芝的有效成分之一, 对人肝癌细胞具有细胞毒作用, 也能抑制组织胺的释放, 具有保肝作用和具有抗过敏作用等。而且本发明饮品中的所加入的成分低聚糖每克只产生0-2.5大卡的热量,不会对血糖值及胰岛素的分泌产生影响,可以做成低热量饮品给糖尿病病人使用。
2、所用的茯苓是野生或生态有机栽培获得的,营养丰富,茯苓能增强机体免疫功能,茯苓多糖有明显的抗肿瘤作用;有利尿作用,能增加尿中钾、钠、氯等电解质的排出;有镇静及保护肝脏、抑制溃疡的发生、降血糖、抗放射等作用。本发明以野生/生态有机种植获得的灵芝、茯苓为原料制作饮品,绿色无公害,经过超微化、胶磨,使饮品中富含水溶性多糖,极易被人体利用,具有降血脂血脂、增强免疫力、抗疲劳、护肠胃等保健功能。本发明的产品配方中不加化学防腐剂和色素,对人体安全,而且饮用方便。
3、本发明生产过程不使用水,以低聚糖为分散剂载体,经过超微粉碎、胶磨均质,使产品中富生物活性成分(多糖、多肽、三萜类、麦角甾醇、甘露醇、黄酮、生物碱等不丢失),具有调节免疫力、抗疲劳、护肝、护肠胃等保健功能。本发明的产品配方中不加化学防腐剂和色素,对人体安全,而且食用比较方便;生产得到的产品保留了灵芝和茯苓的独特风味、口感甘甜爽滑,稳定性好。免蒸煮保留了大量热敏性物质,利用低聚糖的高渗透压保鲜防腐作用,最大限度地保持灵芝、茯苓的生物活性成分物质不受破坏,同时集合了灵芝、茯苓、低聚糖三者之综合功能,起到一举多得的效果。
4、本发明实现了灵芝、茯苓的全原料高效利用,不产生任何废弃物。工艺过程是先将灵芝、茯苓超微粉碎,然后加入低聚糖进行混合;并采用胶体磨磨浆均质,实施胶体化,最后分装铝箔袋或塑料袋,微波杀菌,胶体磨磨浆均质能够使得灵芝、茯苓超微粉均质变成胶体化,并微波杀菌,不容易变质,还可以在胶体化和微波过程中,适当降低水分,保质时间由普通粉碎(300-500目)的产品保质8-10个月延长到15-20个月,产品质量得到很大提高,对人体吸收也大大提高。
5、本发明中,低聚糖又称寡糖,是指含有2-10个糖苷键聚合而成的化合物。低聚糖很难或不会被人体消化吸收,因此,它所提供的能量值很低或根本没有,可在低能量食品中发挥作用,最大限度地满足那些喜爱甜食又担心发胖者的要求,还可供糖尿病人、肥胖病人食用。低聚糖(寡糖)的功能有:1、 调整肠道细菌生态:作为双歧杆菌生长繁殖的养料,抑制有害细菌的生长,增加营养的吸收,并减少肠道有害毒素的产出,延缓老化,维持免疫机能,减少肠道生长恶性肿瘤的危险,和乳酸菌及膳食纤维一样,是整肠、体内环保、促进正常排便的好帮手;2、降血脂:能与胆酸及胆盐结合而将之排除到体外,防止再吸收,并促进胆固醇在肝脏中进行氧化作用产生胆酸,降低血液中胆固醇浓度;3、作为低热量食品及添加剂,寡糖的甜度为蔗糖的20-70%,口感与蔗糖差不多,但不会像蔗糖一样会被口腔中的细菌利用,产生酸性物质侵蚀牙齿,因此不会造成蛀牙。寡糖每克只产生0-2.5大卡的热量,不会对血糖值及胰岛素的分泌产生影响,可以做成低热量食品给糖尿病病人使用;4、增加矿物质的吸收:与膳食纤维相反,寡糖可促进矿物质的吸收。因为寡糖经肠道发酵后可以促成利于矿物质吸收的肠道环境,尤其是钙镁等矿物质。
6、本发明生产方法步骤简单,灵芝、茯苓的利用率高,生产得到的饮品包含了灵芝和茯苓的原汁原味,风味独特、口感甘甜爽滑,营养价值高、稳定性好,含有丰富的灵芝多糖、茯苓多糖,利于被人体利用,能提高人体的免疫力,本发明生产得到的饮品具有护胃、护肝的作用,对细胞免疫和体液免疫功能具有良好的促进作用,具有很好的保健效果。
7、本发明利用富含多糖的灵芝和茯苓为原料配合适量低聚糖(寡糖),制成兼具灵芝多糖、茯苓多糖和低聚糖(寡糖)三重保健功能的饮品,营养、保健功能兼有,特别适合亚健康人群饮用;本发明的生产方法简单快捷,适合大规模工厂化生产。
具体实施方式
实施例1
一种免蒸煮即食型灵芝、茯苓复合健康饮品的生产方法,具体步骤如下:
(1)富含生物活性成分的灵芝粉化:取野生或生态有机种植的干品灵芝,除杂,进行过500目的超微粉碎,取得灵芝超微粉;
(2)富含生物活性成分的茯苓粉化:取野生或生态有机种植的干品茯苓,除杂,进行过500目的超微粉碎,取得茯苓超微粉;
(3)调配:将步骤(1)和(2)得到的超微粉中,按照重量比灵芝超微粉: 茯苓超微粉为1:1的比例调配, 得到混合物,然后再按照混合物:低聚糖为10:100的比例加入低聚糖进行混合;
(4)胶体化:过胶体磨磨浆均质,实施胶体化;
(5)分装杀菌:分装铝箔袋或塑料袋后,于1500w微波下,杀菌35秒,冷却、检验、得到成品。购买回家以后,如果不拆开包装,保质期可以达到15个月以上。
上述的即食型富含生物活性成分的灵芝、茯苓复合健康饮品的生产方法,步骤(2)中所述的灵芝、茯苓为野生/生态有机种植获得的。
实施例2
一种免蒸煮即食型灵芝、茯苓复合健康饮品的生产方法,具体步骤如下:
(1)富含生物活性成分的灵芝粉化:取野生或生态有机种植的干品灵芝,除杂,进行过1000目的超微粉碎,取得灵芝超微粉;
(2)富含生物活性成分的茯苓粉化:取野生或生态有机种植的干品茯苓,除杂,进行过1000目的超微粉碎,取得茯苓超微粉;
(3)调配:将步骤(1)和(2)得到的超微粉中,按照重量比灵芝超微粉: 茯苓超微粉为1:1.5的比例调配, 得到混合物,然后再按照混合物:低聚糖为12:100的比例加入低聚糖进行混合;
(4)胶体化:过胶体磨磨浆均质,实施胶体化;
(5)分装杀菌:分装铝箔袋或塑料袋后,于1500w微波下,杀菌40秒,冷却、检验、得到成品。购买回家以后,如果不拆开包装,保质期可以达到15个月以上。
上述的即食型富含生物活性成分的灵芝、茯苓复合健康饮品的生产方法,步骤(2)中所述的灵芝、茯苓为野生/生态有机种植获得的。
实施例3
一种免蒸煮即食型灵芝、茯苓复合健康饮品的生产方法,具体步骤如下:
(1)富含生物活性成分的灵芝粉化:取野生或生态有机种植的干品灵芝,除杂,进行过1000目的超微粉碎,取得灵芝超微粉;
(2)富含生物活性成分的茯苓粉化:取野生或生态有机种植的干品茯苓,除杂,进行过1000目的超微粉碎,取得茯苓超微粉;
(3)调配:将步骤(1)和(2)得到的超微粉中,按照重量比灵芝超微粉: 茯苓超微粉为1:2的比例调配, 得到混合物,然后再按照混合物:低聚糖为15:100的比例加入低聚糖进行混合;
(4)胶体化:过胶体磨磨浆均质,实施胶体化;
(5)分装杀菌:分装铝箔袋或塑料袋后,于1500w微波下,杀菌35秒,冷却、检验、得到成品。
上述的即食型富含生物活性成分的灵芝、茯苓复合健康饮品的生产方法,步骤(2)中所述的灵芝、茯苓为野生/生态有机种植获得的。购买回家以后,如果不拆开包装,保质期可以达到20个月以上。
实施例4
一种免蒸煮即食型灵芝、茯苓复合健康饮品的生产方法,具体步骤如下:
(1)富含生物活性成分的灵芝粉化:取野生或生态有机种植的干品灵芝,除杂,进行过1500目的超微粉碎,取得灵芝超微粉;
(2)富含生物活性成分的茯苓粉化:取野生或生态有机种植的干品茯苓,除杂,进行过1500目的超微粉碎,取得茯苓超微粉;
(3)调配:将步骤(1)和(2)得到的超微粉中,按照重量比灵芝超微粉: 茯苓超微粉为1:3的比例调配, 得到混合物,然后再按照混合物:低聚糖为10:90的比例加入低聚糖进行混合;
(4)胶体化:过胶体磨磨浆均质,实施胶体化;
(5)分装杀菌:分装铝箔袋或塑料袋后,于1500w微波下,杀菌45秒,冷却、检验、得到成品。
上述的即食型富含生物活性成分的灵芝、茯苓复合健康饮品的生产方法,步骤(2)中所述的灵芝、茯苓为野生/生态有机种植获得的。购买回家以后,如果不拆开包装,置于0-4℃冰箱,保质期可以达到18个月以上。
实施例5
一种免蒸煮即食型富含生物活性成分的灵芝、茯苓复合健康饮品的生产方法,具体步骤如下:
(1)富含生物活性成分的灵芝粉化:取野生或生态有机种植的干品灵芝,除杂,进行过1500目的超微粉碎,取得灵芝超微粉;
(2)富含生物活性成分的茯苓粉化:取野生或生态有机种植的干品茯苓,除杂,进行过1000目的超微粉碎,取得茯苓超微粉;
(3)调配:将步骤(1)和(2)得到的超微粉中,按照重量比灵芝超微粉: 茯苓超微粉为1:3.5的比例调配, 得到混合物,然后再按照混合物:低聚糖为15:100的比例加入低聚糖进行混合;
(4)胶体化:过胶体磨磨浆均质,实施胶体化;
(5)分装杀菌:分装铝箔袋或塑料袋后,于1500w微波下,杀菌40秒,冷却、检验、得到成品。购买回家以后,如果不拆开包装,保质期可以达到20个月以上。
上述的即食型富含生物活性成分的灵芝、茯苓复合健康饮品的生产方法,步骤(2)中所述的灵芝、茯苓为野生/生态有机种植获得的。
实施例6
一种免蒸煮即食型灵芝、茯苓复合健康饮品的生产方法,具体步骤如下:
(1)富含生物活性成分的灵芝粉化:取野生或生态有机种植的干品灵芝,除杂,进行过1000目的超微粉碎,取得灵芝超微粉;
(2)富含生物活性成分的茯苓粉化:取野生或生态有机种植的干品茯苓,除杂,进行过1000目的超微粉碎,取得茯苓超微粉;
(3)调配:将步骤(1)和(2)得到的超微粉中,按照重量比灵芝超微粉: 茯苓超微粉为1:4的比例调配, 得到混合物,然后再按照混合物:低聚糖为15:90的比例加入低聚糖进行混合;
(4)胶体化:过胶体磨磨浆均质,实施胶体化;
(5)分装杀菌:分装铝箔袋或塑料袋后,于1500w微波下,杀菌40秒,冷却、检验、得到成品。购买回家以后,置于冰箱冷藏,保质期可以达到20个月以上。
上述的即食型富含生物活性成分的灵芝、茯苓复合健康饮品的生产方法,步骤(2)中所述的灵芝、茯苓为野生/生态有机种植获得的。
本发明即食型富含生物活性成分的灵芝、茯苓复合健康饮品的效果试验:
有100名志愿者饮用本发明生产得到的富生物活性成分的灵芝、茯苓复合健康饮品,其中有男性、女性各5O名,普遍症状是睡眠不好、失眠多梦、食欲不振、食量少,周身倦怠乏力,精神萎顿、抵抗力差的状况。
上述100人饮用本发明的即食型富生物活性成分的灵芝、茯苓复合健康饮品后,每天每人午间、晚间饭后l小时后饮用一次,每次饮用10毫升,饮用一个月之后,90%的人气色改善,睡眠质量明显提高,食欲不振、精神萎顿等症状基本消失或减轻,不易感冒,而且饮用后均无副作用,胃口变好、精力充沛。
Claims (3)
1.一种即食型灵芝、茯苓复合健康饮品的生产方法,其特征在于,具体步骤如下:
(1)灵芝粉化:取含水率在10%以下的干品灵芝,除杂,进行过500-2000目的超微粉碎,取得灵芝超微粉;
(2)富含生物活性成分的茯苓粉化:取含水率在10%以下的干品茯苓,除杂,进行过500-2000目的超微粉碎,取得茯苓超微粉;
(3)调配:将步骤(1)和(2)得到的超微粉中,按照重量比灵芝超微粉: 茯苓超微粉为1:1-1:5的比例调配, 得到混合物,然后再按照混合物:低聚糖为5-20:50-100的比例加入低聚糖进行混合;
(4)胶体化:过胶体磨磨浆均质,实施胶体化;时间为1小时以上;
(5)分装杀菌:分装铝箔袋或塑料袋后,置于1500w的微波炉,微波杀菌30-60秒,冷却、检验、得到成品。
2.根据权利要求1所述的即食型灵芝、茯苓复合营养饮品的生产方法,其特征在于,步骤(1)(2)中所述的灵芝、茯苓为野生或生态有机种植获得的。
3.根据权利要求1所述的即食型灵芝、茯苓复合营养饮品的生产方法,其特征在于,步骤(3)中所述的低聚糖包括:果糖低聚糖、异麦芽低聚糖、蔗糖低聚糖、牛乳低聚糖、海藻糖、低聚木糖、大豆低聚糖和半乳糖低聚糖。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201610972774.XA CN106509578A (zh) | 2016-10-27 | 2016-10-27 | 即食型灵芝、茯苓复合健康饮品的生产方法 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201610972774.XA CN106509578A (zh) | 2016-10-27 | 2016-10-27 | 即食型灵芝、茯苓复合健康饮品的生产方法 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN106509578A true CN106509578A (zh) | 2017-03-22 |
Family
ID=58349652
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201610972774.XA Pending CN106509578A (zh) | 2016-10-27 | 2016-10-27 | 即食型灵芝、茯苓复合健康饮品的生产方法 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN106509578A (zh) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN110495604A (zh) * | 2018-05-17 | 2019-11-26 | 山东禾桦生物科技有限公司 | 植物素组成物及其制造方法 |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN104432371A (zh) * | 2014-11-14 | 2015-03-25 | 李惠民 | 一种灵芝罗汉果超微粉固体饮料及其制备方法 |
CN105831536A (zh) * | 2016-04-06 | 2016-08-10 | 百色三宝生物技术有限公司 | 一种富硒石斛云耳复合营养饮品的生产方法 |
-
2016
- 2016-10-27 CN CN201610972774.XA patent/CN106509578A/zh active Pending
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN104432371A (zh) * | 2014-11-14 | 2015-03-25 | 李惠民 | 一种灵芝罗汉果超微粉固体饮料及其制备方法 |
CN105831536A (zh) * | 2016-04-06 | 2016-08-10 | 百色三宝生物技术有限公司 | 一种富硒石斛云耳复合营养饮品的生产方法 |
Non-Patent Citations (1)
Title |
---|
陈惠中等: "《餐桌上的中药灵芝》", 31 January 2015, 金盾出版社 * |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN110495604A (zh) * | 2018-05-17 | 2019-11-26 | 山东禾桦生物科技有限公司 | 植物素组成物及其制造方法 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN103740566B (zh) | 一种刺梨药酒及其制作方法 | |
CN102578646B (zh) | 一种保健饮料 | |
CN104997091B (zh) | 蛹虫草速溶固体饮料 | |
CN105167037A (zh) | 一种具有补血养颜功效的姜汁饮料及其制备方法 | |
CN107114783A (zh) | 一种增强免疫及辅助肿瘤恢复的高硒营养补充剂 | |
CN102511867B (zh) | 红枣阿胶枸杞浓浆及其生产工艺 | |
CN103461631A (zh) | 茶糖食品及其制作方法 | |
CN107319086A (zh) | 一种枸杞金丝***压片糖果及其制备方法 | |
CN106615431A (zh) | 一种菊芋片茶及其制作方法 | |
CN101724667A (zh) | 运用生物工程酶技术提取石斛多糖的工艺及其制品和应用 | |
CN107173656A (zh) | 一种中药果蔬益生菌发酵饮品及其制备方法 | |
KR101578070B1 (ko) | 발모 촉진, 탈모 완화 및 개선, 혈당 조절, 위장 장애 증상 완화 및 개선용 건강보조식품 | |
CN102940219A (zh) | 一种土豆饼及其制作方法 | |
CN102511866A (zh) | 红枣阿胶浓浆及其生产工艺 | |
CN102511876B (zh) | 山楂红枣浓浆及其生产工艺 | |
CN104431125A (zh) | 一种沙棘蜂蜜茶及其制备方法 | |
CN106417817A (zh) | 一种袋泡助眠安神茶及其制备方法 | |
KR20180000874A (ko) | 미세먼지 및 중금속과 항생물질 분해 배출에 도움을 주는 영양식품 조성물 및 이를 제조하는 방법 | |
CN109527577A (zh) | 一种具有解酒护肝功能的组合物 | |
CN106509578A (zh) | 即食型灵芝、茯苓复合健康饮品的生产方法 | |
CN104726320B (zh) | 一种无花果蜜醋及制作方法 | |
CN101396056B (zh) | 松针茯苓茶及其制备方法 | |
CN102524869A (zh) | 红枣秋梨枸杞浓浆 | |
CN107095296B (zh) | 富硒红枣枸杞姜汤制作方法 | |
CN101642256A (zh) | 一种去痘美容牛奶的制作方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
RJ01 | Rejection of invention patent application after publication |
Application publication date: 20170322 |
|
RJ01 | Rejection of invention patent application after publication |